Literature DB >> 26615762

Hypoxic preconditioning decreases nuclear factor κB activity via Disrupted in Schizophrenia-1.

Jia-Ren Liu1, Qian Liu2, Joseph Khoury3, Yue-Jin Li3, Xiao-Hui Han3, Jing Li4, Juan C Ibla5.   

Abstract

Nuclear factor κB is a key mediator of inflammation during conditions of hypoxia. Here, we used models of hypoxic pre-conditioning as mechanism to decrease nuclear factor κB activity induced by hypoxia. Our initial studies suggested that Disrupted in Schizophrenia-1 may be induced by hypoxic pre-conditioning and possibly involved in the regulation of nuclear factor κB. In this study we used Disrupted in Schizophrenia-1 exogenous over-expression and knock-down to determine its effect on ataxia telangiectasia mutated--nuclear factor κB activation cascade. Our results demonstrated that hypoxic pre-conditioning significantly increased the expression of Disrupted in Schizophrenia-1 at mRNA and protein levels both in vitro and in vivo. Over-expression of Disrupted in Schizophrenia-1 significantly attenuated the hypoxia-mediated ataxia telangiectasia mutated phosphorylation and prevented its cytoplasm translocation where it functions to activate nuclear factor κB. We further determined that Disrupted in Schizophrenia-1 activated the protein phosphatase 2A, preventing the phosphorylation of ataxia telangiectasia mutated serine-1981, the main regulatory site of ataxia telangiectasia mutated activity. Cellular levels of Disrupted in Schizophrenia-1 protein significantly decreased nuclear factor κB activation profiles and pro-inflammatory gene expression. Taken together, these results demonstrate that hypoxic pre-conditioning decreases the activation of nuclear factor κB through the transcriptional induction of Disrupted in Schizophrenia-1.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ataxia telangiectasia mutated; Disrupted in Schizophrenia-1; Hypoxia; Hypoxic preconditioning; Normoxia; Nuclear factor κB; Protein phosphatase 2A

Mesh:

Substances:

Year:  2015        PMID: 26615762     DOI: 10.1016/j.biocel.2015.11.013

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  1 in total

1.  The Effective Analysis for Blue Honeysuckle Extract in the Treatment of Hepatocellular Carcinoma.

Authors:  Chun-Peng Zhang; Wei-Hua Li; Jia-Ren Liu; Guo-Dong Li; Hao-Peng Zhang; Jiu-Feng Wei; Hong-Sheng Chen; Jin-Lu Zhao; Yun-Feng Wang; Qiang Lv; Ming Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-29       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.